Skip to main content

Table 1 Sample description of 514 people who use opioids in justice diversion addiction treatment during 2014–2016 by gender

From: Justice involvement patterns, overdose experiences, and naloxone knowledge among men and women in criminal justice diversion addiction treatment

 

Total

Women

Men

n (%)

n (%)

n (%)

Total

514 (100)

151 (100)

363 (100)

Justice involvementa

 Age at 1st arrest (years)

  Missing

2 (0.4)

0 (0)

2 (0.6)

  9–17

246 (47.9)

46 (30.5)

200 (55.1)

  18–20

138 (26.9)

48 (31.8)

90 (24.8)

  21–59

128 (24.9)

57 (37.8)

71 (19.6)

  Median (IQR)

18 (16–20.5)

19 (17–22)

17 (15–19)

Lifetime arrests

 Missing

0 (0)

0 (0)

0 (0)

 1–5

173 (33.7)

61 (40.4)

112 (30.9)

 6–10

171 (33.3)

49 (32.5)

122 (33.6)

 11 or more

170 (32.1)

41 (27.2)

129 (35.5)

Arrests in year before treatment or jail

 Missing

3 (0.6)

0 (0)

0 (0)

 0

167 (32.5)

24 (15.9)

143 (39.4)

 1–2

214 (41.6)

77 (51.0)

137 (37.7)

 3–42

130 (25.3)

50 (33.1)

80 (22.0)

 Median (IQR)

1 (0–3)

2 (1–3)

1 (0–2)

Time spent in jail or prison in lifetime (years)

 Missing

7 (1.4)

4 (2.7)

3 (0.8)

 0–0.9

107 (20.8)

66 (43.7)

41 (11.3)

 1–3.4

135 (26.3)

47 (31.1)

88 (24.2)

 3.5–7.4

134 (26.1)

23 (15.2)

111 (30.6)

 7.5–41.3

131 (25.5)

11 (7.3)

120 (33.1)

 Median (IQR)

3.5 (1–7.5)

1.1 (0.3–3)

5 (2.3–9.8)

Time spent in jail or prison in past year (months)

 Missing

17 (3.3)

8 (5.3)

9 (2.5)

 0–1.9

119 (23.2)

43 (28.5)

76 (20.9)

 2–5.9

134 (26.1)

59 (39.1)

75 (20.7)

 6–10.9

125 (24.3)

28 (18.5)

97 (26.7)

 11–12

119 (23.2)

13 (8.6)

106 (29.2)

 Median (IQR)

5.3 (2–10)

3.1 (1.4–6)

6.5 (2.9–12)

Overdose experience

 Experienced an overdose

350 (68.1)

114 (75.5)

236 (65.0)

 Most recent overdose involved heroin and/or prescription opioidsb

254 (72.6)

87 (76.3)

167 (70.8)

 Experienced an overdose in the year before treatment

219 (42.7)

83 (55.0)

136 (37.5)

Number of experienced overdoses in lifetime

 0

164 (31.9)

37 (24.5)

127 (35.0)

 1–5

225 (43.8)

63 (41.7)

162 (44.6)

 6 or more

125 (24.3)

51 (33.8)

74 (20.4)

Witnessed overdose

 Witnessed any overdose

407 (79.2)

127 (84.1)

280 (77.1)

 Most recently witnessed overdose involved heroin and/or prescription opioidsc

339 (83.3)

117 (92.1)

222 (79.3)

Number of witnessed overdoses in lifetime

 0

107 (20.8)

24 (15.9)

83 (22.9)

 1–5

269 (52.3)

84 (55.6)

185 (51.0)

 6 or more

138 (26.9)

43 (28.5)

95 (26.2)

Naloxone knowledge

 Heard of naloxone

319 (62.1)

109 (66.9)

210 (57.9)

 Identified purpose of naloxoned

289 (90.6)

101 (92.7)

188 (89.5)

Demographic and social characteristics

 Age (years), Median (IQR)

34 (27–46)

31 (26–40)

36 (28–48)

Race

 Black

83 (16.2)

18 (11.9)

65 (17.9)

 White

384 (74.7)

116 (76.8)

268 (73.8)

 Other

13 (2.5)

3 (2.0)

10 (2.8)

 Multiple races

34 (6.6)

14 (9.3)

20 (5.5)

 Hispanic ethnicity

24 (4.7)

5 (3.3)

19 (5.2)

 Less than high school education/GED

83 (16.2)

54 (14.9)

29 (19.2)

 Temporary housing in past 3 monthse

290 (56.4)

77 (51.0)

213 (58.7)

Substance use

 Lifetime heroin use

347 (67.5)

117 (77.5)

230 (63.3)

 Heroin use in the past yearf

249 (71.9)

93 (79.5)

156 (67.8)

 Used heroin ≥ 7 consecutive days during the month before treatment or jailf

194 (55.9)

70 (59.8)

124 (53.9)

 Lifetime prescription opioid use (not as prescribed a doctor)

485 (94.4)

144 (95.4)

341 (93.9)

 Used prescription opioids in the past year (not as prescribed by a doctor)g

271 (55.9)

96 (66.7)

175 (51.3)

 Took or borrowed prescription opioids belonging to someone else, took more than prescribed, or used for reasons other than for pain management

371 (72.2)

118 (78.1)

253 (70.0)

 Injected drugs in the month before entering treatment or jail

221 (43.0)

75 (49.7)

146 (40.2)

  1. aLatent class analysis allows for missing values in indicators and uses information on available indicators to create classes for participants with missing data. Therefore, totals for justice involvement may not add to the full sample size
  2. bAmong those who experienced an overdose. Includes most recent experienced overdose events where the participant reported they used heroin and/or prescription opioids. An additional 7 participants (5 men, 2 women) did not report substances used
  3. cAmong those who witnessed an overdose. Includes most recently witnessed overdose events where the participant reported that the victim used heroin and/or prescription opioids. An additional 9 participants (6 men, 3 women) did not know or did not report substances used by the victim
  4. dAmong those who had heard of naloxone
  5. eIncludes living in a halfway house or group home, inpatient facility, jail, shelter, or homeless
  6. fAmong those who used heroin in their lifetime. An additional 16 participants (10 men, 6 women) reported lifetime heroin use but declined to answer questions about past year heroin use. An additional 5 participants (4 men, 1 woman) declined to answer questions about use in the 30 days before entering treatment or jail
  7. gAmong those who used prescription opioids in their lifetime. An additional 19 participants (14 men, 5 women) reported lifetime prescription opioid use but declined to answer questions about past year prescription opioid use